智通财经APP获悉，和铂医药-B(02142)再涨近15%，截至发稿，涨11.73%，报16.19港元，成交额2.78亿港元。
消息面上，和铂医药发布公告，HBM7004用于治疗晚期实体瘤的新药临床试验申请已获国家药监局批准。这是公司在2026年5月8日公告获得美国FDA许可其IND申请后，又一重要进展。
据悉，HBM7004是一款新型B7H4xCD3双特异性抗体，开发自集团专有的HBICE®平台，从疗效和安全性两个维度为癌症免疫治疗提供差异化解决方案。HBM7004的开发进一步彰显了HBICE®平台的灵活适用性和即插即用优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.